New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For SPPI;HNZ;VHC From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
June 29, 2015
07:36 EDTSPPISpectrum coverage assumed with a Buy at H.C. Wainwright
Subscribe for More Information
June 24, 2015
07:02 EDTSPPISpectrum announces publication of Beleodaq data in Journal of Clinical Oncology
Spectrum Pharmaceuticals announced the publication of results from the pivotal BELIEF -- CLN-19 -- Study, which was selected as a Rapid Communication in the Journal of Clinical Oncology, the journal of the American Society of Clinical Oncology. The study, led by Dr. Owen O’Connor from the Center for Lymphoid Malignancies, Department of Medicine, Columbia University Medical Center, New York, NY, showed that monotherapy with Beleodaq produced complete and durable responses with manageable toxicity in patients with R/R PTCL across the major subtypes, irrespective of the number or type of prior therapies. Beleodaq, previously known as belinostat, is a histone deacetylase inhibitor indicated for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma. This indication is approved under accelerated approval based on tumor Response Rate and Duration of Response. An improvement in survival or disease-related symptoms has not been established. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trial. The primary endpoint of the BELIEF study was ORR as assessed centrally by an Independent Review Committee using the International Working Group criteria. The ORR in the 120 evaluable patients was 25.8%, including 13 Complete Responses and 18 Partial Responses. Secondary endpoints included a median DoR of 13.6 months by IWG criteria and 8.4 months to disease progression or death, with the longest ongoing patient at ≥36 months. The most common Grade 3/4 adverse events were anemia, thrombocytopenia, dyspnea, and neutropenia. No clinically relevant ECG changes were identified, and cardiovascular monitoring of ECGs is not required at baseline or during treatment. In this pivotal study, monotherapy with Beleodaq produced complete and durable responses with manageable toxicity in patients with R/R PTCL across the major disease subtypes, irrespective of the number or type of prior therapies and with a low incidence of Grade 3/4 thrombocytopenia.
June 22, 2015
08:02 EDTHNZFirms fight News Corp in contingent-fee suit, Bloomberg reports
Companies such as HJ Heinz (HNZ) and Henkel (HENKY) subsidiary Dial are among the plaintiffs in a class action lawsuit against News Corp (NWS) that claims its advertising unit has monopolized the market for in-store design services, Bloomberg reports. The companies sued in 2013 originally, and the case was granted class action status last Thursday, the report says. Reference Link

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use